European Union - English - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastic agents - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Israel - English - Ministry of Health

raz pharmaceutics ltd, israel - carmustine - powder and solvent for concentrate for solution for infusion - carmustine 100 mg - carmustine - carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved agents in the following:• brain tumors - glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumors.• multiple myeloma - in combination with glucocorticoid such as prednisone. • hodgkin’s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.• non-hodgkin’s lymphomas - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.

Israel - English - Ministry of Health

mbi pharma ltd., israel - carmustine - powder and solvent for concentrate for solution for infusion - carmustine 100 mg/vial - carmustine - carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved agents in the following:• brain tumors - glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumors.• multiple myeloma - in combination with glucocorticoid such as prednisone. • hodgkin’s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.• non-hodgkin’s lymphomas - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy

Israel - English - Ministry of Health

k.s.kim international ltd - carmustine - powder and solvent for concentrate for solution for infusion - carmustine 100 mg - carmustine - carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved agents in the following:• brain tumors - glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumors.• multiple myeloma - in combination with glucocorticoid such as prednisone. • hodgkin’s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.• non-hodgkin’s lymphomas - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - powder and solvent for concentrate for solution for infusion - carmustine 100 mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - carmustine - powder and solvent for concentrate for solution for infusion - carmustine

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - carmustine - powder and solvent for concentrate for solution for infusion - carmustine

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - carmustine - powder and solvent for concentrate for solution for infusion - carmustine

Ireland - English - HPRA (Health Products Regulatory Authority)

tillomed pharma gmbh - carmustine - powder and solvent for concentrate for solution for infusion - 100 milligram(s) - nitrosoureas; carmustine

Israel - English - Ministry of Health

megapharm ltd - carmustine - wafer - carmustine 7.7 mg - carmustine - carmustine - for use as an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated. gliadel implant is indicated in newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation. gliadel implant is indicated for use as an adjunct to surgery in patients with recurrent histogically proved glioblastoma multiforme for whom surgical resection is indicated.